Large gap with delayed quotes
|
Last quote
12/26/2024 -
20:00:00
|
Bid
12/27/2024 -
07:08:20
|
Bid Volume |
Ask
12/27/2024 -
07:08:20
|
Ask Volume |
|---|---|---|---|---|
|
7.72
+0.05
(
+0.65% )
|
7.62
|
200 |
7.71
|
200 |
Analysis date: 24.12.2024
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 24.12.2024.
Interest
Strong
Strong
Strong interest since 24.12.2024.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 24.12.2024 at a price of 7.67.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 10.12.2024), the stock traded above its moving average. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 7.435.
4wk Rel Perf
4.62%
4.62%
The four week relative overperformance versus SP500 is 4.62%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 17.12.2024.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 5.57%.
Mkt Cap in $bn
1.61
1.61
With a market capitalization <$2bn, BIOCRYST PHARMA is considered a small-cap stock.
G/PE Ratio
3.03
3.03
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
30.21
30.21
The estimated PE is for the year 2026.
LT Growth
91.67%
91.67%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
9
9
Over the last seven weeks, an average of 9 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
121
121
For 1% of index variation, the stock varies on average by 1.21%.
Correlation
0.22
0.22
Stock movements are strongly independent of index variations.
Value at Risk
3.93
3.93
The value at risk is estimated at USD 3.93. The risk is therefore 51.17%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
16.09.2014
16.09.2014